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Regenerative Medicine In Argentina: Making 
Experience Work 
Shawn H.E. Harmon♠ 
Prof. Graeme T. Laurie♣ 
Policy Brief No. 4:2008 
Drawing on research conducted at SCRIPT and discussions undertaken at the “Regulation of Clinical Research Involving Stem 
Cells: An International Workshop”, held in Buenos Aires on 29-30 November 2007, this Policy Brief places the regulation of 
stem cell research in the broader bioscience and health research context, highlights what have proven to be effective policy 
approaches in the UK, identifies some core issues in translating policy objectives into legal regulation, and offers several 
recommendations to facilitate the design of effective human tissue (and stem cell) regulation in Argentina (and Latin America 
more generally). 
WHY DO THE EXPERIENCES OF OTHERS MATTER? 
 
It is trite to confirm that there is no need to re-invent the wheel; regulatory re-
invention is fruitless, not only for the time and institutional energy that it 
consumes, but for the real risk of repetition of mistakes that others have 
already made.  In short, it can be entirely appropriate to examine others’ 
governance processes, instruments and victories/failures.  Indeed, given the 
internationalisation of science and the (attempted) harmonisation of laws in a 
variety of relevant areas, not least bioethical boundary-setting and intellectual 
property protection, observation, adaptation and selective emulation in the 
regulatory field is more apt than ever before. 
 
Jurisdictions considering regulation in the realm of regenerative medicine and 
human tissue use – such as Argentina – should note that many jurisdictions 
have developed human tissue governance regimes in an ad hoc piecemeal 
manner.  In particular, the UK’s regime has become cumulative and complex 
with many competing influences.  There is value in examining that system for 
the lessons to be learned from its lengthy legislative experience, while 
remaining cognizant of the particular political, economic and social/cultural 
settings that might influence the Argentine setting. 
 
By doing so, Argentina can streamline its legislative process, adopting and 
modifying what has proven best and most effective and rejecting a priori what 
has proved ineffective or would be inappropriate in the Argentine context.  
Ultimately, the “design” of legal frameworks that can be “trusted” in other 
jurisdictions will facilitate the growth of Argentine science and the transport of  
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1. The term “trusted” here recognises the international nature of science, production and markets, 
and refers to the creation of a regime that stakeholders in target jurisdictions can be satisfied will, 
in the usual course, result in reliable scientific outputs (ie: outputs that have been adequately 
ethically considered and are scientifically sound). 
2. Available at www.epo.org/patents/law/legal-texts/html/epc/1973/e/ma1.html. 
3. Directive 98/44 EC on the Legal Protection of Biotechnology Inventions, 6 July 1998, available 
at http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31998L0044:EN:HTML. 
its resultant products/processes.1 
 
WHAT ARE THE KEY FEATURES OF THE UK SYSTEM? 
 
The UK human tissue and health innovation regimes encompass adult, fetal 
and cadaveric tissue use for research and/or transplantation, the use of 
embryos for research and treatment, and the use of body products (urine, 
blood, etc.) for research and/or transplantation.  The regulatory landscape is 
populated by the Human Fertilisation and Embryology Authority (HFEA), 
the Human Tissue Authority (HTA), the UK Stem Cell Bank (UKSCB), the 
General Medical Council (GMC), the National Research Ethics Service 
(NRES), the Medicines and Healthcare Products Regulatory Agency 
(MHRA), and various (local) Research Ethics Committees (RECs), to name 
the most important.  Commercialisation, particularly patenting, is influenced 
by the European Patent Convention (1973),2  European legislation,3  and by 
decisions from the European Patent Office (EPO) and UK Intellectual 
Property Office (UK-IPO). 
 
From a procedural point of view, key features of UK governance of human 
tissue use are: 
 
• its reliance on statutory authorities to remove (many) decisions from the 
legislative arena, absorb debate and tensions, and de-politicise (to the 
extent possible) administration; 
 
• its up-front approval (RECs), threshold or licensing requirements 
(HFEA), and on-going inspectorate functions (HFEA, HTA) to judge 
competence and monitor compliance; 
 
• its relatively frequent utilisation of public consultation to test satisfaction 
and preferred direction of scientific and regulatory endeavour; and 
 
• its complex and multi-actor setting. 
 
From a more substantive point of view, key features are: 
 
• its liberal but pragmatic and flexible approach, placing degrees of 
discretion in the hands of the relevant authorities to act within their 
sphere of competence; 
 
• its reliance on the human rights paradigm as a legislative touchstone and 
its “fetishisation” of consent as a consequence thereof; 
 
• its inability to imagine a research setting without property/ownership; 
 
• its “pragmatic” or “loose” articulation of key underlying values (ie: its 
identification of the “special status” of the embryo has allowed the system 
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4. H. Whittall, “The UK Stem Cell Research Regime”, for Argentine Ministry of Science & 
Technology, “Regulation of Clinical Research Involving Stem Cells: An International”, 
International Workshop, 29-30 November 2007, Buenos Aires.  
5. See EPO, Scenarios for the Future (Munich: EPO, 2007), which attempts to imagine possible 
future worlds and the place of the patent system in them.  Future scenarios explored are: (1) 
business as the dominant driver, (2) geopolitics as the dominant driver, (3) society as the 
dominant driver, and (4) technology as the dominant driver. 
to work well for some 17 years); 
 
• its increasing subjugation to European Union legislative influences (eg: it 
is estimated that 80% of regulation in the biomedical sphere comes from 
the EU). 
 
Key lessons from the UK experience (not only in the human tissue context, 
but in the biotech context more generally) are that dialogue and clear 
identification of purpose deliver a reasonably good system.4   Open dialogue, 
transparent processes, clear (or identifiable) reasoning, and forthright 
articulation of regulatory objectives lend the eventual regulatory regime 
legitimacy even if disagreement over the policy-making process or regulatory 
content persists. 
 
WHAT ISSUES ARE HIGHLIGHTED BY THE  
UK’S EXPERIENCE? 
 
Despite generally working well, the UK’s regulatory system does not currently 
optimise the translation of research into socially useful new technologies.  
Three major regulatory hurdles are: 
 
• Regulatory Joined-Up-ness: There exists “innovation drag” as a result of 
regulatory complexities (eg: regulatory overlap and co-regulation by a 
variety of bodies, from the HFEA and HTA, to the UKSCB, to the 
GMC, the UKIPO and EPO, and more).  The inefficiencies created by 
multiple overlapping recommendations, directions, guidance, and laws 
from bodies/agencies (who do not necessarily coordinate or even 
communicate) with an interest in different but overlapping stages of 
innovation, complicate and elongate the journey from idea to socially-
useful output.  It also makes it difficult for public actors to steer 
innovation derived from tissue in socially-useful directions. 
 
• Role of Research Ethics Committees: A particular pressure point in the 
field of translating research into products/processes directed at humans is 
the remit and transparency of local or multi-centre RECs; more 
particularly, how to articulate the scope of the former and ensure the 
latter. 
 
• Access to Research Data: There are substantial barriers to 
researcher/innovator access to data, and much work has been done with a 
view to examining the knowledge enclosure tendencies of existing 
intellectual property regimes.5  
 
Additionally, the optimal governance of human tissue use and health 
innovation implicates a host of ethical challenges, some of which are 
currently unevenly addressed.  Five core challenges are: 
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6. Academy of Medical Sciences, Personal Data for Public Good: Using Health Information in 
Medical Research (2006), at http://www.acmedsci.ac.uk/p99puid62.html. 
7. Article 29 Data Protection Working Party, Working Document on the Processing of Personal 
Data Relating to Health in Electronic Health Records (2007), at 
http://ec.europa.eu/justice_home/fsj/privacy/docs/wpdocs/2007/wp131_en.pdf. 
8. G. Laurie et al., “Tackling Community Concerns About Commercialisation and Genetic 
Research: A Modest Interdisciplinary Proposal” (2007) 64 Social Science and Medicine 272-282. 
9. http://www.innogen.ac.uk. 
• Consent:  The imperative to obtain informed consent has become the 
dominant paradigm in biomedical governance, but its application to 
research involving health data or human tissue should be explored in 
more depth. Such an imperative may stand in the way of valuable 
regenerative medicine research and act as a hurdle to striking an optimal 
balance of interests.  Consent is not a social value in itself, but merely a 
means to respect individuals; it is neither necessary nor sufficient to 
protect the core individual interests involved in research involving health 
data, viz privacy interests. Its importance for the removal of human tissue 
is self-evident, but its continuing role to regulate storage and use is less 
obvious. We suggest a frank exploration of the value and limits of consent 
and how its value and role may changes across regulatory contexts. 
 
• Confidentiality:  As the UK Academy of Medical Sciences recently 
reported,6  the regulatory regime that operates within the UK with respect 
to privacy does not take advantage of flexibilities within the law which 
provide for the protection of privacy while also promoting medical 
research when informed consent is neither practicable nor possible.  
Similarly, recent work on e-health records outlines the possibilities for 
regulatory regimes in promoting a public interest mandate.7   Ultimately, a 
balance of public and private interests must be sought. 
 
• Confidence:  Public trust and confidence is crucial to effective governance 
and we suggest that close attention should be paid to questions of access 
to data, whether derived directly from medical information or indirectly 
from human tissue.  Good governance regimes should be transparent, 
robust, reasonable, involve clear due process for all parties, and be subject 
to effective oversight.  We point to the UK Biobank Ethics and 
Governance Council, chaired by Prof. Graeme Laurie, which is 
developing considerable experience in this realm; crucial to the success of 
the Council is a close working relationship with UK Biobank itself. 
 
• Commercialisation:  Our research, and that of others, has revealed some 
evidence of public unease about the role and consequences of 
commercialisation of biomedical (and particularly genomic) research.8   
While we accept commercialisation as a reality, we suggest that the careful 
consideration over whether and how such public attitudes might be taken 
into account is necessary.  Clearly, public attitudes in the UK say nothing 
about public attitudes in Argentina, but much can be learned from the 
work of centres such as ESRC/InnoGen, which have built up 
considerable expertise in conducting public engagement exercises.9  
 
• Collaboration:  International collaboration is essential to realising the full 
promise of regenerative medicine.  The same is true in terms of 
governance, and in many ways the UK is leading the international field; 
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10. For more on the Population Project in Genomics, see http://www.p3gconsortium.org/.
11. And terrible mistakes have been made by the uncritical transposition of frameworks from one 
socio-economic setting to another in the economic and development context: see M. Minogue & 
L. Cariño (eds.), Regulatory Governance in Developing Countries (Cheltenham: Edward Elgar, 
2006). 
12.  www.berr.gov.uk/. 
13.  www.ukcrc.org/. 
once again, one can point to the UK Biobank Ethics and Governance 
Council, and also to the international example of the Public Population 
Project in Genomics (P3G), which is seeking harmonisation of efforts, 
both scientific and regulatory, among biobanks across the globe.10   
International collaboration on access – both to data and samples – is one 
of the current challenges facing global scientific progress.  Regulatory 
harmonisation – or at least mutual recognition and reciprocity – are at the 
heart of these debates. 
 
WHAT ISSUES ARE APPARENT IN THE  
ARGENTINE SETTING? 
 
As noted above, the particulars of the political, economic and social/cultural 
setting within which regulation must operate must be taken into account.11   
Our own research and the representations at the Regulation of Clinical 
Research Involving Stem Cells Workshop (Buenos Aires) expose the 
following as important objectives, concerns and issues in the Argentine 
context: 
 
• Leadership: There is a desire to (1) increase the effectiveness of Argentine 
healthcare and thereby realise better health, (2) improve Argentine 
innovation pathways/systems so as to push economic growth through 
(health) scientific progress, and (3) to heighten the quality of Argentine 
science, thereby achieving international recognition and serving as a 
regional leader. 
 
• Cultural Contradiction:  Despite their widespread (and sometimes 
unlawful) use, reproductive technologies are highly contested and give rise 
to sensitive issues in Argentina, and one might expect regenerative 
technologies, which are closely linked thereto, to trigger similar 
contradictions.  Although such an environment demands policy-makers to 
grapple with complexity and diversity, public debates over the moral 
status of the embryo need not necessarily be rehearsed (as they can never 
lead to answers or consensus).  Much may be learned from the pragmatic 
approach adopted in the UK and its regulatory systems which emphasise 
scientific robustness and ethical approval  mechanisms as thresholds for 
permitting research. 
 
• Regulatory Turbulence:  The existing regulatory landscape contains gaps 
and instabilities, including over-extension of existing regulatory bodies 
(such as Agencia, INCUCAI and ANMAT), insufficient communication 
between existing bodies, and unclear lines of authority as tissue moves 
between different bodies across the research field.  The UK faces similar 
challenges, but two initiatives designed to easy the regulatory burden 
merit further investigation, being the Department for Business Enterprise 
and Regulatory Reform (BERR)12  and the UK Clinical Research 
Collaboration (UKCRC),13  both of which are concerned with 
streamlining the regulatory environment.  
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14. The WHO has encouraged openness of information on clinical trials so that research can be 
linked and researchers can avoid duplication of projects (and therefore of evidence). 
15. Consider the utility of social scientists “problemitising” issues and investigating public 
perceptions around them as a means of enriching the policy dialogue and the quality, and 
therefore the durability, of regulation. 
 
• Ethical Concerns: Regulatory turbulence contributes to ethical concerns 
insofar as questionable regulator remit leads to inconsistent standards and 
an inability to rely on what has happened under different regimes (or at 
different stages in the innovation pipeline), all of which gives rise to the 
formation of ethical grey zones. 
 
• Practical Research Guidance:  Scientists would benefit from clear 
guidance with respect to (1) the types of evidence needed before moving 
from one stage of a trial to another, (2) the role of placebos in trials, (3) 
the level of evidence required for approval of SC therapies, (4) adequate 
dissemination of trials being carried out,14  (5) the building of a culture of 
communication wherein the state, universities, research centres and 
scientists take an active lead.  Guidance is only helpful, however, if is 
comes from a body with sufficient authority among the relevant 
regulatory players and if it provides sufficient clarity for action and 
responsibility; more guidance does not necessarily led to more or better 
science. 
 
RECOMMENDATIONS FOR ARGENTINA’S  
STEM CELL REGIME 
 
Based on the above, we would make the following recommendations: 
 
• Communication and Dialogue:  It can sometimes take a long time for 
debates to mature; in the UK, embryonic stem cell research was preceded 
by the Warnock Committee’s work on reproductive technologies in the 
mid-1980s, and evolved as the technology and moral thinking around it 
advanced.  While such a long percolation period is not appropriate for 
Argentina given the advanced state of the science, a culture of 
communication is nonetheless essential.  A discourse which incorporates 
hopes, actions for generating identified products and processes, and, 
importantly, foundational values, permits different stakeholders to offer 
different information/truth;15  it can promote compromise, and it does 
promote transparency and the commitment of resources to publicly 
identified purposes with clear public benefit. 
 
• Governance and Democratisation:  Science is not neutral; its direction 
and the core of its inquiries are as much a function of culture and politics 
as of truth.  Similarly, politics and power impact on how regulation is 
made and therefore on the content of that regulation.  Both science and 
regulation are most robust and responsive to public needs when they have 
been discussed and shaped by an informed polity.  As noted above, open 
dialogue with stakeholders can clearly influence the direction of science 
and the content of its regulation.  More importantly, where public-minded 
bodies take a lead in that dialogue, it can ensure that science and 
regulation is not “captured” by parochial interests. It will be important 
and valuable for Argentina to map the range of stakeholders, their 
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16. And it has been noted that, in the regenerative medicine research context, the regulatory 
instrument should apply equally to publicly and privately funded research and to publicly and 
privately operated biobanks, with a clear articulation of quality standards and risk issues attaching 
to research materials on the one hand and therapeutic materials on the other. 
interests and value-preferences in order to anticipate and respond 
effectively when developing policy pathways in the realm of regenerative 
medicine and human tissue use. 
 
• Efficiency and Integration:  It is essential to be aware of the myriad ways 
in which regenerative medicine research and its regulation interacts with 
other existing, emerging or planned regulatory mechanisms; this promotes 
timely and valuable innovation.  Argentina has the opportunity to map its 
existing regulatory pathways and to identify how more effective and 
efficient (or “joined up”) regulatory instruments might be developed 
which links innovation from idea, to basic research, to product/process 
development, to clinical trial, to commercialisation, to market.  A single 
legislative framework with built-in flexibilities (to promote durability) 
preceded by a statement of principles may be ideal.16   
 
• Supportive and Creative:  There is a need for the regulatory regime to be 
both supportive and creative.  Rather than a risk-obsessed “red light” 
scheme, it must be a positive, objective-oriented system which promotes a 
supportive environment to allow people to think creatively and 
innovatively within defined parameters.  It must also be internally creative 
insofar as it links into other regimes and offers opportunities for new 
pathways (eg: Argentina might examine the operation of the intellectual 
property regime in this field and its interaction with international 
institutions, considering how experiments in other jurisdictions, such as 
the UK Stem Cell Bank’s reliance on Open Science, might be taken 
forward in Argentina to benefit its science sector and its public).17 
 
17. Exercises in foresight are important, but should not be extended too far or approached linearly, 
for innovation (and the production of regulation) is a complex undertaking with many variables.  
With respect to foresight, see R. Williams, “Compressed Foresight and Narrative Bias: Pitfalls in 
Assessing High Technology Futures” (2006) 15 Science as Culture 327-348. 
 
 
 
This Policy Brief forms part of the programme of work of the 
“Governing Emerging Technologies: Social Values and Stem 
Cell Regulation in Argentina” project funded by the ESRC 
(Award No. RES-000-22-2678) and supported by 
AHRC/SCRIPT and InnoGen.   
For more on the GET: Social Values project, visit  
http://www.law.ed.ac.uk/ahrc/esrcvaluesproject/relatedproject 
This Policy Brief forms part of the programme of work of the 
“Protection, Promotion and Regulation of Biotechnology in 
Developing Countries” project undertaken at AHRC/SCRIPT.   
 
For more on the ProReg Biotech project, visit 
http://www.law.ed.ac.uk/ahrc/research/viewprojects.aspx?id=13 
and 
http://www.law.ed.ac.uk/ahrc/esrcvaluesproject/relatedprojects.asp.
